Profiling the Acute Effects of Modified Risk Products: Evidence from the SUR-VAPES (Sapienza University of Rome-Vascular Assessment of Proatherosclerotic Effects of Smoking) Cluster Study.
Cluster analysis
Electronic cigarette
Electronic vaping cigarette
Heat-not-burn cigarette
Modified risk product
Smoking
Tobacco
Journal
Current atherosclerosis reports
ISSN: 1534-6242
Titre abrégé: Curr Atheroscler Rep
Pays: United States
ID NLM: 100897685
Informations de publication
Date de publication:
07 02 2020
07 02 2020
Historique:
entrez:
9
2
2020
pubmed:
9
2
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Modified risk products (MRP) are promoted as a safer alternative to traditional combustion cigarettes (TCC) in chronic smokers. Evidence for their lower hazardous profile is building, despite several controversies. Yet, it is unclear whether individual responses to MRP differ among consumers. We hypothesized that different clusters of subjects exist in terms of acute effects of MRP. Pooling data from a total of 60 individuals, cluster analysis identified at least three clusters (labelled 1 to 3) of subjects with different electronic vaping cigarettes (EVC) effects and at least two clusters (labelled 4 to 5) of subjects with different heat-not-burn cigarettes (HNBC) effects. Specifically, oxidative stress, platelet aggregation, and endothelial dysfunction after EVC were significantly different cluster-wise (all p < 0.05), and oxidative stress and platelet aggregation after HNBC were significantly different (all p < 0.05). In particular, subjects belonging to Cluster 1 appeared to have less detrimental responses to EVC usage than subjects in Cluster 2 and 3, as shown by non-significant changes in flow-mediated dilation (FMD) and less marked increase in Nox2-derived peptide (NOX). Conversely, those assigned to Cluster 3 had the worst reaction in terms of changes in FMD, NOX, and P-selectin. Furthermore, individuals belonging to Cluster 4 responded unfavorably to both HNBC and EVC, whereas those in Cluster 5 interestingly showed less adverse results after using HNBC than EVC. Results for main analyses were consistent employing different clusters, tests, and bootstrap. Individual responses to MRP differ and smokers aiming at using EVC or HNBC as a risk reduction strategy should consider trying different MRP aiming at finding the one which is less detrimental, with subjects resembling those in Cluster 1 preferably using EVC and those resembling Cluster 5 preferably using HNBC.
Identifiants
pubmed: 32034541
doi: 10.1007/s11883-020-0824-4
pii: 10.1007/s11883-020-0824-4
doi:
Substances chimiques
P-Selectin
0
SELP protein, human
0
CYBB protein, human
EC 1.6.3.-
NADPH Oxidase 2
EC 1.6.3.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
8Références
Eur Heart J. 2019 Apr 1;40(13):1069-1077
pubmed: 30689812
J Am Heart Assoc. 2019 Mar 19;8(6):e010455
pubmed: 30879375
Int J Cardiol. 2018 Jul 1;262:57-63
pubmed: 29622508
Tob Control. 2020 Mar;29(2):140-147
pubmed: 30760629
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
Addict Behav. 2015 Jan;40:57-65
pubmed: 25222849
Circ Cardiovasc Qual Outcomes. 2017 Jan;10(1):
pubmed: 28093398
Tob Control. 2020 Jan;29(1):89-95
pubmed: 30696783
N Engl J Med. 2018 Sep 06;379(10):991-2
pubmed: 30188641
Am J Physiol Heart Circ Physiol. 2019 Apr 1;316(4):H801-H827
pubmed: 30707616
Annu Rev Public Health. 2018 Apr 1;39:215-235
pubmed: 29323609
Chest. 2015 Sep;148(3):580-582
pubmed: 25836723
Chest. 2015 Sep;148(3):582-584
pubmed: 25837266
J Am Coll Cardiol. 2015 Mar 31;65(12):1268-1269
pubmed: 25814238
Chest. 2016 Sep;150(3):606-12
pubmed: 27108682
Lancet. 2013 Nov 16;382(9905):1629-37
pubmed: 24029165
Curr Atheroscler Rep. 2019 Mar 16;21(5):15
pubmed: 30877398
Tob Induc Dis. 2018 May 08;16:18
pubmed: 31516418
J Am Coll Cardiol. 2014 Oct 28;64(17):1765-74
pubmed: 25443696
BMJ. 2017 Jul 26;358:j3506
pubmed: 28747300
PLoS One. 2016 Feb 03;11(2):e0145881
pubmed: 26840410
Adv Respir Med. 2019;87(2):123-134
pubmed: 31038725
N Engl J Med. 2018 Jan 18;378(3):216-219
pubmed: 29342380
Minerva Cardioangiol. 2019 Aug;67(4):318-329
pubmed: 29687698
Lancet. 2017 May 13;389(10082):1885-1906
pubmed: 28390697
JAMA Netw Open. 2019 Mar 1;2(3):e191047
pubmed: 30924893
Minerva Cardioangiol. 2018 Jun;66(3):292-300
pubmed: 29160047
Sci Rep. 2017 Mar 07;7:43965
pubmed: 28266630
Am J Cardiol. 2018 Nov 1;122(9):1477-1481
pubmed: 30170691
J Am Coll Cardiol. 2019 Jun 4;73(21):2722-2737
pubmed: 31146818